Healthcare / Drug Manufacturers - Specialty & GenericBSE
$162.30
-3.05 (-1.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-57.8M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$958M
P/E
78.8x
↑EV/EBITDA
6.2x
↓ROE
3.2%
↑Gross Margin
53.4%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
—
FCF margin
7.5%
FCF / Net income
4.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.41B · net income $23.5M · FCF $105.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.41B | $1.41B | $1.21B | $1.04B | $1.01B |
| Net Income | $23.5M | $23.5M | $74.9M | $-62.6M | $-47.5M |
| EBITDA | $164.5M | $164.5M | $194.8M | $25.8M | $55.2M |
| EPS | — | — | 12.70 | -10.62 | -7.90 |
| Gross Margin | 53.4% | 53.4% | 55.2% | 36.8% | 38.7% |
| Operating Margin | 7.3% | 7.3% | 3.0% | -3.1% | -0.7% |
| Net Margin | 1.7% | 1.7% | 6.2% | -6.0% | -4.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.07 | 0.31 | 0.19 |
| Current Ratio | 2.56 | 2.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $105.8M | $105.8M | $-80.2M | $-57.8M | $-215.3M |
| Returns | |||||
| ROE | 3.2% | 3.2% | 10.6% | -9.9% | -6.9% |
| Valuation | |||||
| P/E | 78.79 | 78.79 | 10.63 | — | — |
| EV/EBITDA | 6.18 | 6.18 | 4.33 | 36.19 | 13.63 |
| P/B | 1.31 | 1.31 | 1.13 | 1.18 | 0.90 |
| Growth & Yield | |||||
| Revenue Growth | 16.4% | 16.4% | 16.4% | 2.9% | — |
| EPS Growth | — | — | 219.6% | -34.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.0%
Start / end P/E
n/dx → n/dx
EPS bridge
12.70 → n/d
Residual
+1.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.